Mohamed Allaf: Aspirin and Clopidogrel Show Comparable Long-Term Survival After TAVI
Mohamed Allaf, Associate College Tutor at Royal College of Physician, Director of Specialtyapp, Internal Medicine Residency at NHS England, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in adding:
“To the best of our knowledge, this is the largest study comparing aspirin versus clopidogrel following TAVI.
Our analysis showed comparable long-term survival in patients treated with either aspirin or clopidogrel.
Further randomized trials are required for the validation of our results.”
Title: Aspirin Versus Clopidogrel as Single Antiplatelet Therapy After TAVI: A Propensity Score-Matched, Retrospective Analysis
Article: Anastasios Apostolos, Konstantinos Konstantinou, Mohammed Allaf, Athanasios Sakalidis, Konstantinos Kalogeras, Ee Ling Heng, Simon Davies, Alison Duncan, Miles Dalby, Saeed Mirsadraee, Tarun Mittal, Aigul Baltabaeva, Tito Kabir, Mohammed Majid Akhtar, Robert Smith, Vasileios Panoulas
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 9, 2026, 18:10James P. Crowley: How Turmeric and Green Tea May Affect Blood Sugar and Blood Pressure
-
Aug 9, 2026, 18:08Ahmed Alotaibi: How Many Lives Could Nationwide Prehospital Blood Access Potentially Save?
-
Aug 9, 2026, 18:06Are We Measuring What Matters Most in ITP? – ITP Australia and New Zealand
-
Aug 9, 2026, 18:00Sangeeta Pathak: Delivering a Talk on Sustainable Blood Systems and Haemovigilance
-
Aug 9, 2026, 15:33Tareq Abadl: Kell System and Anti-K Alloimmunization
-
Aug 9, 2026, 15:16Antonella Cordoba: Emicizumab and the Evolving Landscape of Hemophilia A
-
Aug 9, 2026, 14:53Daniel Pereira Monteiro: Understanding Isoelectric Focusing in Hemoglobin Testing
-
Aug 9, 2026, 14:23Retheesh DasÖ‰ Edema Is a Sign, Not a Diagnosis
-
Aug 9, 2026, 13:56Binay Shah: Building a Future of Accessible Cancer Care